Obesity and related diseases burden both society and the individual, increasing the prevalence and risk of comorbidities including diabetes, heart disease, and cancer ([@B1]). It is clear that obesity and hyperinsulinemia are closely related, although their causal relationship remains poorly defined, obscuring the molecular mechanisms underlying possible treatments for obesity. The common belief is that obesity precedes insulin resistance, which subsequently causes a compensatory increase in β-cell insulin secretion to prevent hyperglycemia ([@B2]). However, elevated circulating insulin levels have been reported prior to the onset of obesity ([@B3], [@B4]), and increasing evidence suggests that hyperinsulinemia is not simply an adaptive response to obesity ([@B5]). In support of this concept, adipose tissue--specific impairment of insulin signaling prevents obesity in mice ([@B6][@B7][@B8][@B9]--[@B10]). Furthermore, we recently reported that mice with lifelong prevention of diet-induced hyperinsulinemia by partial insulin gene deletion were protected against high-fat diet (HFD)--induced obesity ([@B11], [@B12]). These results provided the first evidence in mammals that hyperinsulinemia itself plays a causal role in obesity, yet this preventative approach could not determine whether insulin reduction could serve as a viable treatment in those individuals who are already obese. Suppressing hyperinsulinemia with drugs has been used as an obesity treatment in animal models and in some human studies ([@B13][@B14]--[@B15]). However, these results must be interpreted with caution, because these drugs directly affect other organs that are also implicated in weight regulation, including white adipose tissue (WAT) and the hypothalamus ([@B13], [@B16]). Herein, we report, that an adult-onset partial reduction of insulin (*Ins*)-*2* gene dose in obese male mice caused significant weight loss within 5 wk, with specific effects on visceral adipose depots. The results demonstrate that adiposity and obesity can be controlled by modest changes in circulating insulin.

MATERIALS AND METHODS {#s1}
=====================

Animals and *in vivo* physiology {#s2}
--------------------------------

Animal protocols were performed in accordance with the University of British Columbia Animal Care Committee. *Ins1^−/−^*:*Ins2^fl/+^* mice have been described in Duvillié *et al*. ([@B17]). *Pdx1*Cre^ERT^ mice (024968) and mice carrying the lineage-tracing marker membrane-targeted tdTomato/membrane-targeted enhanced green fluorescent protein; (mTmG; 007675) were purchased from The Jackson Laboratories (Bar Harbor, ME, USA). Before they were randomized into different groups, they were fed a 19% protein extruded rodent diet (Teklad; Envigo, Madison, WI, USA). At 6 wk of age, male mice were randomized and placed on 1 of 3 diets: *1*) a 10% fat diet \[total calories = 3.85 kcal/g; 10% calories from fat, 20% from protein, and 70% from carbohydrate; D12450B (Open Source/Research Diets, New Brunswick, NJ, USA)\], *2*) a 25% fat diet \[total calories = 3.70 kcal/g; 25% calories from fat, 20% from protein, and 55% from carbohydrate; 5LJ5 (Lab Diet, St. Louis. MO, USA)\], *3*) a 58% fat diet \[total calories = 5.56 kcal/g; 58.0% calories from fat, 16.4% calories from protein, and 25.5% calories from carbohydrate; D12330 (Open Source Diets/Research Diets)\]. Mice that were randomized were born from 5 breeding pairs, and we ensured that pups of subsequent litters were placed on each of the three different diets before repeating any diet twice. The body mass of the mice before randomization ranged from 21.4 to 33.2 g. Because our study primarily focused on the physiologic changes in mice fed an HFD, we can report that, immediately upon randomization, the average body weights were as follows: vehicle, 26.5 ± 0.5 g; control, 26.8 ± 0.3 g; and experimental, 26.1 ± 0.3 g. Twelve weeks after the initiation of this diet, control (*Ins1^−/−^*:*Ins2^fl/+^*:mTmG) and experimental (*Ins1^−/−^*:*Ins2^fl/+^*:*Pdx1*Cre^ERT^:mTmG) mice were injected intraperitoneally with tamoxifen (3 mg/40 g body weight) dissolved in corn oil for 4 consecutive days. Body mass was measured between 6 and 23 wk of age between 2 and 4 [pm,]{.smallcaps} and daily food intake was measured 2 wk before and 4 wk after tamoxifen injections. Basal blood glucose measurements and blood collection to measure circulating insulin were performed after the mice remained unfed for 4 h. Glucose tolerance and insulin sensitivity were assessed in mice injected with 20% glucose and 1.5 U/kg body weight insulin, respectively, after 4 h without food. Glucose-stimulated insulin secretion was assessed in mice injected with 20% glucose after 4 h without food. Insulin content from *in vivo* isolated islet samples was measured with ELISA kits from Alpco (Salem, NH, USA). Leptin, resistin, ghrelin, glucose-dependent insulinotropic peptide (GIP), glucagon-like protein (GLP)-1, IL-6, and pancreatic polypeptide (PYY) were measured with a mouse magnetic bead panel assay and Luminex technology (Millipore-Sigma, Billerica, MA, USA). IL-1β, TNF-α, Il-2, IL-6, and IL-12^p70^ levels were measured with a mouse magnetic bead panel (Bio-Rad, Hercules, CA, USA). Nonesterified fatty acids (NEFAs; Wako, Richmond, VA, USA), free glycerol and glycerides (Millipore-Sigma) were measured according to the manufacturer's protocol in serum collected from a cohort of mice fed an HFD 5 wk after tamoxifen injections and not fed for 16 h and again for 15 min after insulin stimulation (2 U/kg body weight). Adipose mass was measured from this cohort of mice.

Fluorescence microscopy {#s3}
-----------------------

Pancreata from PBS-perfused mice were harvested and fixed in 4% paraformaldehyde for 24 h, washed, and stored in 70% ethanol, before paraffin embedding. Sections (5 μm) were taken from at least 3 different regions of the pancreas, 100 μm apart. Sections were deparaffinized, hydrated with decreasing concentrations of ethanol, and rinsed in PBS, then exposed to a 15 min heat-induced epitope retrieval at 95°C with 10 mM citrate buffer (pH 6.0). Sections were blocked and incubated with primary anti-insulin (ab7842; Abcam, Cambridge, MA, USA) and anti-green fluorescent protein (GFP) (A11122; Thermo Fisher Scientific, Waltham, MA, USA) overnight in a humid chamber at 4°C. Primary antibodies were visualized after incubation with secondary antibodies conjugated to AlexaFluor 488, 555, 594, or 647, as required (1:1000; Thermo Fisher Scientific). Gonadal and perirenal adipose tissue was harvested from mice left unfed for 4 h, and tissues were fixed in 4% paraformaldehyde. Adipocyte size was measured by staining for perilipin in 5 mm-thick sections (Cell Signaling Technology, Danvers, MA, USA). All images were taken on ImageXpress^micro^ with a ×10 high (NA 0.3) objective.

Immunoblot analyses and protein detection {#s4}
-----------------------------------------

In Western blot analyses, 30--40 μg of protein was used to probe for polymerase I and transcript release factor (PTRF; ab48824; Abcam); the ratio of phospho-caveolin-1 (3251) to total caveolin-1 (3267, clathrin (4796), insulin receptor (3020), ratio of phospho-hormone--sensitive lipase (Hsl;4139) to total Hsl (4107), ratio of phospho-Akt (4060) to total Akt (9272), and ratio of phospho-p44/42 MAPK (4370) to total p44/42 MAPK (4695; all from Cell Signaling Technology); and lipoprotein lipase (Lpl; sc-32885; Santa Cruz Biotechnology, Dallas, TX, USA) in gonadal tissue from mice that were left unfed overnight and during a 15-min insulin-stimulation (2 U/kg body weight). Actin (NB600-501; Novusbio, Littleton, CO, USA) and vinculin (13901; Cell Signaling Technology) were used as loading references.

Islet isolation, culture, and perifusion {#s5}
----------------------------------------

Pancreatic islets were isolated by using collagenase, filtration, and manual picking ([@B18]). Islets were cultured overnight (37°C, 5% CO~2~) in RPMI 1640 medium (Thermo Fisher Scientific) with 11 mM glucose (Millipore-Sigma), 100 U/ml penicillin, 100 μg/ml streptomycin (Thermo Fisher Scientific), and 10% fetal bovine serum (Thermo Fisher Scientific). *In vitro* insulin secretion was measured by perifusion and radioimmunoassay ([@B19]).

RNA isolation, real-time quantitative PCR, and transcriptome analysis {#s6}
---------------------------------------------------------------------

Total RNA was isolated from islets with an RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada). Reverse transcription was used to generate cDNA (Superscript III; Thermo Fisher Scientific). TaqMan probes (Integrated DNA Technologies, Coralville, IA, USA) were used to measure *Ins2* gene expression, with actin as a reference gene. Gonadal adipose tissue was dissected from a cohort of 23-wk-old (corresponding to 5 wk after tamoxifen injection) control littermate (*n* = 7) and experimental (*n* = 8) mice euthanized after remaining unfed for 4 h. RNA isolation was performed with Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and Qiagen RNeasy Mini Kit (Qiagen). In brief, tissue was homogenized in Trizol and centrifuged for 10 min at 4°C. Chloroform was added to the supernatant and centrifuged for 15 min at 4°C. An equal volume of 70% ethanol was added to the aqueous layer after chloroform extraction, and this mixture was transferred to the spin column. The remainder of the protocol was followed as in the manufacturer's instructions. cDNA synthesis and real-time quantitative PCR was conducted as published ([@B11]). For RNA sequencing, libraries were prepared with the TruSeq RNA Sample Preparation v.2 kit (Illumina, San Diego, CA, USA), from 400 ng of total RNA. Sample quality was assessed with a BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA), and RNA was quantified with Qubit (Thermo Fisher Scientific). Libraries were multiplexed and sequenced over two rapid-run lanes on HiSeq2500, and raw data were converted to fastq format with bcl2fastq-v1.8.4 (Illumina). Kallisto software (*<https://pachterlab.github.io/kallisto/>*) was used for read alignment and expression quantification and the R package DESeq2 software (*<http://bioconductor.org/packages/release/bioc/html/DESeq.html>*) for differential expression analysis. In brief, kallisto (version 0.42.3) was used to build an index file for the mouse reference transcriptome GRCm38 \[downloaded from Ensembl (*[www.ensembl.org](http://www.ensembl.org)*)\]. The sequence reads for each sample were then quantified with the quant function of kallisto. In-house Perl scripts were used to sum the read counts at the transcript level for each gene and to create a matrix comprising the read counts for all the genes for all the samples. Differential expression analysis was then performed on the data from that matrix by using DESeq2. Each sample was assessed with the quality control software RNA-SeQC (The Broad Institute, Cambridge, MA, USA; *<http://archive.broadinstitute.org/cancer/cga/rna-sequc>*) and the PtR script from the Trinity Suite (*<http://TrinityRNASeq.sourceforge.net>*). Quality control showed one control and two experimental outliers, and these samples were removed from differential expression analyses. Therefore, included in the analyses are expression from 6 control and 6 experimental mice. RNA sequencing transcriptome data were analyzed with GeneMania (*<http://genemania.org/>*), to construct a predicted protein--protein networking model which was manually arranged into groups based on predicted tissue origin.

Micro-computed tomography and dual-energy X-ray absorptiometry {#s7}
--------------------------------------------------------------

Scans were performed with a TriFoil Micro-Computed Tomography (CT) scanner (Northridge Tri-Modality Imaging, Inc., Chatsworth, CA, USA) with the following settings: resolution, 50 μm; scan time,∼4 min. Each mouse was scanned 1 wk before and again 5 wk after tamoxifen injections. The mice were positioned on their backs in the scanner with a straight spine and a minimum 90° angle between the spine and the femur bone, which was confirmed by a scout scan. Animals were scanned while anesthetized (O~2~ at 1.0 L/min; 5% isoflurane). Analysis of the scanned images was performed with Amira 6.0.1 software (FEI, Hillsboro, OR, USA). The first transsectional scan showing the pelvis was set as the reference scan for each mouse. The inner layers of the abdominal wall were applied to distinguish visceral from subcutaneous fat depot volumes (µm^3^). Lean mass was determined *in vivo* by dual-energy X-ray absorptiometry (Lunar Piximus; no longer manufactured) densitometer in mice 5--7 wk after tamoxifen (from 15 control and 12 experimental mice).

Statistical analysis {#s8}
--------------------

Data are expressed as means ± [sem]{.smallcaps} unless otherwise indicated. Results were considered statistically significant at *P* \< 0.05, by 2-tailed, unpaired Student's *t* test. Statistical analyses were performed with Microsoft Excel (Redmond, WA, USA).

RESULTS AND DISCUSSION {#s9}
======================

Inducible, partial *Ins2* gene deletion as an experimental model to reduce insulin production {#s10}
---------------------------------------------------------------------------------------------

To directly assess the sustained effects of hyperinsulinemia on obesity and weight loss, we generated a mouse model in which the insulin gene dose could be reduced by using an inducible Cre-loxP system ([**Fig. 1*A***](#F1){ref-type="fig"}). At 6 wk of age, mice were fed 1 of 3 diets; low fat (10%), moderate fat (25%), or high fat (58%). After 12 wk of consuming these diets, littermate control (*Ins1^−/−^*:*Ins2^f/+^*:mTmG) and experimental (*Ins1^−/−^*:*Ins2^f/+^*:*Pdx1*Cre^ERT^:mTmG) male mice were injected intraperitoneally with tamoxifen, resulting in a near complete recombination on this genetic background ([Fig. 1*B*](#F1){ref-type="fig"}) ([@B20]).

![Adult reduction of *Ins2* gene dose in mice consuming low- and moderate-fat diets does not reverse weight gain. *A*) Schematic of our hypothesis that reduced insulin would reverse weight gain and obesity in adult male mice fed a low-fat (10%, yellow), moderate-fat (25%, light blue), or high-fat (58%, dark blue) diet. *B*) Tamoxifen induction of *Pdx1*Cre^ERT^ led to near complete, as evidenced by membrane GFP expression (bottom). *C*) Insulin content in mice (*n* = 7, 6; control *n* is listed first throughout) fed a moderate-fat diet were measured from isolated islets 40 wk after tamoxifen injections. For insulin content measurements, *n* represents individual mice. *D*) Circulating insulin at 5, 25, and 40 wk after tamoxifen injection in control littermates (*n* = 10--15) and experimental mice (*n* = 7--12) fed a moderate-fat diet. *E*, *F*) Glucose tolerance (*E*) and insulin sensitivity (*F*) in mice (*n* = 15, 12). Insets: area under the curve (AUC) (*E*) and area over the curve (AOC) (*F*). *G*) Glucose-stimulated insulin secretion (*n* = 15, 12). *H*) Percentage change in body mass of male mice fed a moderate-fat diet; control littermates (*n* = 20; *Ins1^−/−^*:*Ins2^f/+^*:mTmG; gray dashed line) and experimental mice (*n* = 20; *Ins1^−/−^*:*Ins2^f/+^*:*Pdx1*Cre^ERT^:mTmG; blue dashed line). *I*) Percentage change in body mass of male mice fed a low-fat diet; control littermates (*n* = 3; *Ins1^−/−^*:*Ins2^f/+^*:mTmG; gray dashed line) and experimental mice (*n* = 2; *Ins1^−/−^*:*Ins2^f/+^*:*Pdx1*Cre^ERT^:mTmG; yellow line). Unless otherwise indicated, measurements were conducted from samples collected from mice between 5 and 7 wk after tamoxifen injection. Data are means ± [sem]{.smallcaps}.](fj.201700518Rf1){#F1}

Inducible partial loss of *Ins2* does not affect the weight of mice fed a moderate- or low-fat diet {#s11}
---------------------------------------------------------------------------------------------------

Manipulation of *Ins2* gene dose in experimental mice fed a moderate-fat diet did not significantly affect islet insulin levels ([Fig. 1*C*](#F1){ref-type="fig"}), nor did this manipulation lead to a statistically significant alteration in circulating insulin in experimental mice throughout the study ([Fig. 1*D*](#F1){ref-type="fig"}). Consistent with these findings, glucose tolerance, insulin sensitivity, and glucose-stimulated insulin secretion were not impaired in experimental mice when compared to control littermates in the context of this diet ([Fig. 1*E--G*](#F1){ref-type="fig"}). Reduction of *Ins2* gene dose in male mice did not affect body mass in mice fed a moderate-fat diet ([Fig. 1*H*](#F1){ref-type="fig"}). Similarly, body mass was unchanged after a reduction in the *Ins2* gene dose in experimental mice fed a low-fat diet ([Fig. 1*I*](#F1){ref-type="fig"}). These results are in line with previous evidence from other genetic manipulations that do not affect body mass in mice fed low- or moderate-fat diets ([@B21]).

Inducible *Ins2* gene reduction modestly reduces islet insulin secretion in mice fed an HFD {#s12}
-------------------------------------------------------------------------------------------

*Ins2* gene reduction in male mice fed an HFD resulted in a significant (30%) reduction of *Ins2* expression ([**Fig. 2*A***](#F2){ref-type="fig"}) and a similar magnitude, but nonsignificant, reduction in insulin protein content from isolated islets ([Fig. 2*B*](#F2){ref-type="fig"}) compared to littermate controls. The modest reduction in insulin gene expression in experimental mice led to a significant reduction in the second phase of high glucose-stimulated insulin secretion ([Fig. 2*C*](#F2){ref-type="fig"}). We detected significantly lower levels of fasting insulin *in vivo* at 25 wk after tamoxifen injection, although we noted high variability in the fasting insulin measurements at all ages ([Fig. 2*D*](#F2){ref-type="fig"}). These modest reductions in insulin secretion were not sufficient to alter glucose tolerance, insulin sensitivity, or glucose-stimulated insulin secretion ([Fig. 2*E--G*](#F2){ref-type="fig"}). We were also unable to detect any differences in the levels of several other circulating hormones, including leptin, resistin, ghrelin, GIP, GLP-1, IL-6, and PYY ([Fig. 2*H*](#F2){ref-type="fig"}). Thus, in these experimental conditions, partial ablation of the *Ins2* gene in adult mice results in small but significant reductions in basal and glucose-stimulated second-phase insulin release that remain within the normal range for glucose homeostasis. The maintenance of normal glucose homeostasis within our model allowed us to test for the causality of hyperinsulinemia in obesity, without confounding changes in glucose tolerance or insulin sensitivity.

![Adult reduction of *Ins2* gene dose in mice fed an HFD impairs the second phase of high-glucose--stimulated insulin secretion without altering glucose tolerance and insulin sensitivity. *A*) Islet *Ins2* transcript level in control littermates (*n* = 15, *Ins1^−/−^*:*Ins2^f/+^*:mTmG; gray) and experimental mice (*n* = 16; *Ins1^−/−^*:*Ins2^f/+^*:*Pdx1*Cre^ERT^:mTmG; blue) fed an HFD were measured from isolated islets of mice 5 wk after tamoxifen injections. *B*) Islet insulin content of mice (*n* = 15, 17; control *n* is listed first throughout) fed an HFD were measured from isolated islets of mice 5 wk after tamoxifen injections. For insulin content and transcript level measurements, *n* represents individual mice. *C*) *In vitro* basal, glucose- (15 mM) and KCl- (30 mM) stimulated insulin release from isolated islets (*n* = 3, 3). *D*) Fasting circulating insulin 5, 25, and 40 wk after tamoxifen injection in control littermate (*n* = 7--19) and experimental mice (*n* = 5--14). *E*, *F*) Glucose tolerance (*E*) and insulin sensitivity (*F*) in mice (*n* = 14, 19). Insets: area under the curve (AUC) (*E*) and area over the curve (AOC) (*F*). *G*) Glucose-stimulated insulin secretion in mice (*n* = 26, 19). *H*) Leptin, resistin, ghrelin, GIP, GLP-1, IL-6, PYY levels in plasma extracted from control littermates (*n* = 6--10) and experimental mice (*n* = 7--12). Unless otherwise indicated, measurements were conducted from samples collected from mice between 5 and 7 wk after tamoxifen injection. Data are means ± [sem]{.smallcaps}. \**P* \< 0.05.](fj.201700518Rf2){#F2}

Inducible insulin reduction causes weight loss in mice fed an HFD {#s13}
-----------------------------------------------------------------

To test our hypothesis that obesity could be reversed by acutely suppressing insulin, we examined the body weight of HFD-fed control littermates and experimental mice 5 wk after tamoxifen injections. In a pilot study, we found that tamoxifen injection resulted in a slight reduction in body mass compared to that in vehicle-treated mice ([Supplemental Fig. S1](#SM1){ref-type="supplementary-material"}). To be conservative, we felt it was most appropriate to compare groups of mice that were both injected with tamoxifen. Using this conservative approach, we found that acute reduction in *Ins2* gene dose resulted in an ∼5% reduction in body mass ([**Fig. 3*A***](#F3){ref-type="fig"}). Control mice had body weights ranging from 42 to 44 g, whereas experimental mice weighed between 39 and 41 g 5 wk after the tamoxifen injection. The weight loss we observed in the experimental mice was primarily related to the reduced mass of gonadal and perirenal fat pads, which were significantly lighter than those fat pads isolated from controls ([Fig. 3*B*](#F3){ref-type="fig"}). Micro-CT imaging confirmed reduced visceral fat accumulation in mice after partial *Ins2* gene ablation ([Fig. 3*C*](#F3){ref-type="fig"}). The masses of liver, heart, and brain (data not shown), as well as brown adipose tissue (BAT) ([Fig. 3*C*](#F3){ref-type="fig"}), were not affected by reducing the *Ins2* gene dose. In addition, mean lean mass measurements in dual-energy X-ray absorptiometry scans did not differ between control littermate and experimental mice (30.9 ± 0.6 *vs.* 29.7 ± 0.7 g). There were no differences in daily food intake before or after recombination ([Fig. 3*D*](#F3){ref-type="fig"}), suggesting the absence of a robust action on the brain. Analysis of gonadal and perirenal fat pad cross sections did not reveal robust differences in adipocyte morphology between control littermate and experimental mice ([Fig. 3*E*](#F3){ref-type="fig"}). Together, these data demonstrate that a modest acute reduction of circulating insulin can lead to weight loss. Our data are consistent with the reduced obesity in HFD-fed mice with β-cell specific loss of glutamate dehydrogenase 1 (Glud1), an enzyme required for complete insulin secretion ([@B22]).

![Adult reduction of *Ins2* gene dose reverses obesity in mice fed an HFD, primarily because of reduced mass of gonadal and perirenal fat pads. *A*) Percentage change in mass of control littermate (*n* = 39) and experimental (*n* = 29) mice 5 wk after tamoxifen injection. *B*) Inguinal, gonadal, perirenal, and mesenteric WAT depots and BAT from mice were weighed after 16 h without food and again at 15 min after an insulin stimulation (*n* = 16, 11). *C*) Representative transsectional images obtained by micro-CT (left) and quantification (right) of percentage change in subcutaneous and visceral fat depots after tamoxifen injection (*n* = 14, 17). *D*) Daily food intake was measured for 2 wk before, and 4 wk after, tamoxifen injection (*n* = 14, 19; control *n* is listed first throughout). Arrow: the week of tamoxifen injection. *E*) Representative sections of gonadal (*n* = 7, 10) and perirenal (*n* = 8, 11) adipose tissue (top; hematoxylin and eosin staining) and analysis of adipocyte size distribution (bottom; perilipin staining). *F*--*H*) NEFA (*F*), free glycerol (*G*), and glyceride (*H*) levels (*n* = 6, 8) were measured after food was withheld for 16 h and again 15 min after insulin stimulation. Unless otherwise indicated, measurements were conducted in samples collected from mice between 5 and 7 wk after tamoxifen injection. Data are means ± [sem]{.smallcaps}. \**P* \< 0.05.](fj.201700518Rf3){#F3}

Markers of lipid mobilization are altered after induced insulin reduction {#s14}
-------------------------------------------------------------------------

Insulin regulates lipid metabolism at multiple steps, including by inhibiting lipolysis ([@B23]). Basal levels of NEFA, free glycerol, or glycerides ([Fig. 3*F--H*](#F3){ref-type="fig"}) did not differ between control littermates and experimental mice, indicating that the reduction of circulating insulin in the experimental mice did not grossly impair lipid metabolism and that insulin sensitivity remained similar between these two groups of mice. Insulin is well known to regulate WAT lipid accumulation ([@B24]). This, along with the reduction of fat mass in the experimental mice, led us to explore proteins involved in adipocyte energy storage and lipid mobilization. First, we examined the protein abundance of Ptrf/Cavin, given that both mice and humans with loss-of-function mutations in this gene display a lipodystrophic phenotype ([@B25], [@B26]). Indeed, Ptrf protein levels were significantly lower in experimental mice after reduction of *Ins2* gene dose ([**Fig. 4*A***](#F4){ref-type="fig"}). Ptrf is known for its role in the formation and organization of caveolae, together with caveolin proteins, which have also been implicated in lipodystrophy ([@B27][@B28]--[@B29]). In addition to clathrin, phosphorylated caveolin-1 has been implicated recently in insulin uptake and insulin receptor internalization ([@B30], [@B31]). However, we did not observe significant differences in the protein abundances of clathrin, caveolin 1 (Cav1), Y14 phosphorylated Cav1, insulin receptor, phosphorylated-Akt, or phosphorylated-Erk between control littermates and experimental mice. This result suggests that Ptrf either acts downstream of reduced insulin independent from Cav1 or in a manner that does not necessitate changes in Cav1 protein levels or phosphorylation at the Y14 site. It is also consistent with our observations that insulin sensitivity was not influenced by our mild and acute reductions in insulin production. Nevertheless, caveolin proteins have been implicated in the activation of lipolysis ([@B32]) and Hsl ([@B33]). Phospho-Hsl did not differ statistically between control littermates and experimental mice, consistent with the similarities in plasma levels of free fatty acids and glycerol ([Fig. 3*F*, *G*](#F3){ref-type="fig"}). We observed a slight reduction (*P* = 0.06) in Lpl in our experimental mice compared with their control littermates, suggesting another mechanism associated with altered lipid uptake into adipose tissue in the context of reduced insulin production and secretion. Given the role of Lpl as an important marker for adipogenesis ([@B34]), the reduced levels in our study may reflect impaired adipogenesis related to reduced insulin production and secretion ([@B35]).

![Network analysis of gonadal fat pad from adult mice with reduced *Ins2* gene dose. *A*) Representative immunoblots (left) and quantification (right) of key proteins involved in lipid metabolism. *B*) Analysis of a protein--protein interaction network assembled from RNAseq data. Node color reflects whether mRNA is increased (green) or decreased (red); gray represents linking genes. *C*) IL-1β, TNF-α, Il-2, IL-6, and IL-12^p70^ levels in control littermate (*n* = 8--9) and experimental (*n* = 7--12) mice.](fj.201700518Rf4){#F4}

Inducible insulin reduction is associated with an altered immune profile in adipose tissue {#s15}
------------------------------------------------------------------------------------------

We performed RNA sequencing to further examine the effects of inducible insulin reduction on the transcriptome of gonadal fat tissue 5 d after tamoxifen injection. After correction for multiple testing, we did not find any individual genes that were significantly differentially expressed when the *Ins2* gene dose was reduced. However, ordering the genes by *P*-value before correction for multiple testing revealed that some gene families were overrepresented at the top of that list ([Supplemental File S1](#SM1){ref-type="supplementary-material"}). We therefore selected the top 24 genes, all with uncorrected *P* \> 0.01, for protein--protein network modeling, to visualize the relationships between the expressed mRNAs; these networks were manually arranged to reflect the most likely cell source, based on the GTEx (*<http://www.gtexportal.org>*) resource. Six immune-associated genes, including chemokine ligand (*Ccl*)*25*, interferon-induced protein with tetratricopeptide repeats (*Ifit*)*-2*, *Ifit3*, *Ifit3b*, Ig-like domain-containing receptor (*Ildr*)-*2*, and inter-α-trypsin inhibitor heavy chain (*Itih*)*-3* were down-regulated in the experimental mice compared to control littermates within the subnetwork of a predicted leukocyte source ([Fig. 4*B*](#F4){ref-type="fig"}). Enriched pathways in the protein--protein network highlighted changes in immune function as well as lipid transport ([**Table 1**](#T1){ref-type="table"}). *Ccl25* is primarily involved in leukocyte migration and its elevated expression is associated with chronic inflammatory conditions ([@B36]). Inflammatory conditions linked to the onset of diabetes in nonobese Goto-kakizaki rats are also associated with elevated expression of *Ifit* genes ([@B37]) and *Itih3* and *Itih4* genes have been linked to obesity ([@B38]) and diabetes ([@B39]) in mouse genetic studies. These genes bind to locally synthesized hyaluronan and, as a complex, have been reported to be involved in inflammatory diseases ([@B40]). Levels of hyaluronan, an extracellular matrix component, have been reported to increase in adipose tissue ([@B41]) as well as insulin-resistant skeletal muscle in mice with diet-induced obesity ([@B42]). Our control littermates are both obese and hyperinsulinemic compared with our experimental mice, which is consistent with altered expression of proinflammatory genes. The down-regulation we observed of immune-related genes in mice with reduced insulin, however, did not correspond to statistically significant changes in individual cytokines measured within gonadal tissue homogenates ([Fig. 4*C*](#F4){ref-type="fig"}). Although we did not observe the stereotypical increase in uncoupled protein 1 expression ([Supplemental File S1](#SM1){ref-type="supplementary-material"}) in our experimental mice, we noted differential expression of *Ildr2*, a gene associated with white adipose browning. Specifically, the expression level of *Ildr2* has been noted to be significantly lower in BAT than in subcutaneous and visceral WAT depots ([@B43]). Furthermore, we noted an increase in neuregulin (*Nrg*)-2 gene expression within the predicted adipocyte source. Nrg2 belongs to the neuregulin family of proteins (Nrg1--4) which shares N-terminal epidermal growth factor (EGF)-like domains, which activates membrane-associated tyrosine kinases related to the EGF receptors ([@B44]). Nrg4 has been characterized as a WAT browning adipokine ([@B43], [@B45]), and its overexpression has been linked to reduced chronic inflammation in preventative and treatment studies ([@B46]). Nrg2, like Nrg4, has been implicated in neurite outgrowth and may increase adipose tissue innervation, which is necessary for the initiation of WAT lipolysis ([@B47]). The RNA-sequencing data and network analysis suggest the potential for interesting differences in adipose tissue function and composition, although, clearly, additional targeted loss-of-function studies are needed to establish if any of these gene products mediate the effects of reduced insulin on body weight.

###### 

Enriched pathways in the protein--protein network in gonadal fat from mice with reduced insulin

  Gene feature                                         FDR
  ---------------------------------------------------- ----------
  Blood microparticle                                  4.24E−09
  Lipid transporter activity                           1.73E−02
  Lipid transport                                      2.62E−02
  Steroid binding                                      2.62E−02
  Triglyceride-rich lipoprotein particle               4.78E−02
  Very-low-density lipoproteins particle               4.78E−02
  Neutral lipid metabolic process                      6.20E−02
  Response to virus                                    6.20E−02
  Extracellular matrix                                 6.20E−02
  Cyclin-dependent protein kinase holoenzyme complex   6.20E−02
  Acylglycerol metabolic process                       6.20E−02
  Lipid localization                                   6.20E−02
  Plasma lipoprotein particle                          6.51E−02
  Phospholipid binding                                 6.97E−02
  Protein--lipid complex                               7.08E−02
  Intestinal absorption                                7.74E−02
  Adenylyltrasnferase activity                         7.74E−02
  Lipoprotein particle receptor binding                8.96E−02

Our data provide the first molecular genetic evidence that obesity can be reversed by acutely and modestly reducing insulin production alone. The results of this treatment study, combined with our previous prevention studies ([@B11], [@B12]), clearly demonstrate the causal control of obesity by hyperinsulinemia in a genetically tractable mammalian system. The magnitude of insulin gene dose reduction achieved in our current study (∼30%) does not cause changes in glucose homeostasis and is attainable in human populations as a preventative measure or weight-loss strategy. For example, intermittent and continuous energy restriction over a 6-mo period resulted in similar reductions in circulating insulin in obese patients, coupled with a 5--10% loss in body weight ([@B48]). Although such dietary restriction interventions are often associated with high dropout rates ([@B49]), isocaloric restriction of daily fructose intake from 28 to 10% is an alternate approach that may mitigate high dropout rates and has successfully been shown to achieve similar reductions in circulating insulin and weight loss in obese adolescent patients ([@B50]). The magnitude of weight loss in our study, when translated to humans, has been associated with improvements to risk factors linked to cardiovascular disease, as well as reductions in the risk of developing type 2 diabetes by more than 50% ([@B51]).

CONCLUSIONS {#s17}
===========

Our results have profound implications for nutritional guidelines and therapeutic efforts to combat obesity and its comorbidities. Our findings support the concept that an individual's hyperinsulinemia status should be the target for lifestyle modifications, macronutrient dietary composition, and drug development for the purposes of weight loss. Studies where individualized dietary responses are assessed ([@B52]) and mechanistically defined will be useful for the design of personalized nutrigenomic strategies. Approaches that physiologically modulate insulin levels may also have therapeutic utility beyond weight loss, including in the improvement of insulin sensitivity, and perhaps even longevity ([@B53]).
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